Business
Natera Announces Commercial Launch of Zenith™ Genomics for Rare Disease Diagnosis
New genomic testing solution designed to shorten diagnostic journeys for patients and families; supports efforts to reduce the economic and societal burden
About this update from Natera, Inc.
[{"type":"text","content":"\nNew genomic testing solution designed to shorten diagnostic journeys for patients and families;\n\n\nsupports efforts to reduce the economic and societal burden of rare diseases in the U.S.A.\n\n\n AUSTIN, Texas--(BUSINESS WIRE)--\nNatera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the commercial launch of Zenith genomics, its next-generation whole genome sequencing assay designed to significantly improve the detection of rare diseases. Natera is presenting on Zenith’s unique platform and performance at the 2026 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting, taking place this week in Baltimore, Maryland.\n\n\nZenith genomics was built to address one of the most critical challenges in medicine: timely and accurate diagnosis of rare genetic conditions. Rare diseases affect an estimated 30 million Americans annually1, many of whom experience prolonged diagnostic odysseys (4-7 years on average). The cumulative economic burden of rare diseases in the United States was nearly $997 billion in 2019, including $449 billion in direct medical costs and $548 billion in indirect and non-medical costs, underscoring the scale of unmet need and societal impact.1\n\n\nPowered by advanced sequencing and interpretation technology, Zenith genomics provides enhanced resolution of typically hard to detect features such as tandem repeat expansions by using long-read sequencing confirmation to provide comprehensive diagnostic clarity. It utilizes a whole genome sequencing backbone, allowing the most comprehensive analysis, and can support diagnosis of many rare and ultra-rare diseases, guidance for targeted therapies and improved long-term clinical management.\n\n\nThe underlying technology supporting Zenith genomics was developed by MyOme, a leading clinical whole genome analysis company helping families understand disease risk. Through this exclusive partnership, Natera will bring Zenith genomics to healthcare providers across the United States, leveraging its extensive electronic medical records (EMR) integration footprint, robust clinical support system and unparalleled experience in high-complexity genomics. This unified infrastructure supports efficient ordering to complement Natera’s other genomic offerings, enhancing value for clinicians, patients a...